the global dermatology drugs market is expected to advance rapidly during the forecast period (2018–2023). The market is predicted to advance at the CAGR of 8.2% during the forecast period, from its recorded value of $21.5 billion in 2017, to reach $34.5 billion by 2023.

Receive Sample Copy of this Report: https://www.psmarketresearch.com/market-analysis/dermatology-drug-market/report-sample

The increasing prevalence of skin diseases is one of the biggest factors boosting the growth of the dermatology drugs market. Trauma, environmental and genetic factors, and aging are some of the most significant factors causing skin diseases in millions of people across the globe. As per the observations of the World Health Organization (WHO), skin diseases are one of the most common forms of health disorders and they affect nearly 900 million people at a time, around the world.

Make an Enquiry before Purchase: https://www.psmarketresearch.com/send-enquiry?enquiry-url=dermatology-drug-market

Based on treatment, the dermatology drugs market is divided into multiple categories, namely retinoids, calcineurin inhibitors, hormonal therapy, topical corticosteroids, biologics, antihistamines, and others, wherein the others category includes antifungal, antibacterial, and antiviral agents and enzyme inhibitors. Amongst the different categories, topical corticosteroids had the largest share in the market, in terms of revenue, in 2017. This was primarily due to the rise in the demand for these drugs as a result of the growing prevalence of eczema across the world.

Report Description: https://www.psmarketresearch.com/market-analysis/dermatology-drug-market

On the basis of drug, the dermatology drugs market is categorized into Remicade, Dupixent, Canesten, Neoral, Stelara, Zyvox, Cubicin, Cosentyx, Enbrel, Eucrisa, Humira, Valtrex, Otezla, Taltz, Protopic, and others. Out of these, Humira accounted for the largest market share, in terms of revenue, in 2017. The reason behind this drug’s market control was its high demand from psoriasis patients, as this drug is used for the treatment of adults suffering tom moderate-to-severe chronic plaque psoriasis as well as those who qualify for systemic therapy or phototherapy.